Across the US, the UK, and parts of Europe, CGT progress is being held back by an inability to secure starting material ...
The late-stage MonumenTAL-3 trial of Talvey (talquetamab), given in combination with J&J and Genmab's anti-CD38 antibody ...
Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...
Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...
Novo Nordisk has become the latest pharma group to be targeted by a cyberattack, with the company revealing that some patient ...
Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...
In a paper published in the journal Lingua, researchers at the University of Surrey polled 300 patients who used a chatbot ...
There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...
AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for ...
San Francisco-based SonoThera closed an oversubscribed $125 million Series B financing round, saying it will use the proceeds ...
Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor – was more effective than Sotyktu ...
AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results